Abstract
Some of biotech' s most celebrated successes include:
- clotting factors
- anticoagulants
- modern insulins
- growth hormone
- follicle-stimulating hormone
- hematopoietic growth factors
- interferons
- interleukins
What do they have in common? They are therapeutic proteins, a market segment
that had $34 billion in sales in 2004 and will have a projected $52.2 billion
in sales in 2010*. As patents on first-generation proteins wind down, their
owners naturally seek to protect their markets against interlopers. And in
current and future battles for market share, protein delivery technologies are
major weapons of offense and defense. It is a safe bet that if a therapeutic
protein is bringing in big money and its patent is nearing expiration, someone
somewhere with a clever technology is planning a market invasion based on
improving how the protein is delivered. Delivery Technologies for Therapeutic
Proteins: Assessment and Outlook analyzes and assesses protein delivery
technologies developed by companies that are targeting:
- improved insulin delivery
- improved erythropoietin delivery
- improved interferon delivery
- improved growth hormone delivery
The report also analyzes and assesses noninjection delivery technologies,
including technologies for:
- transdermal protein delivery
- oral protein delivery
- pulmonary protein delivery
- nasal protein delivery
Delivery Technologies for Therapeutic Proteins: Assessment and Outlook
provides a thorough analysis and assessment of technologies for protein
half-life extension and technologies for delivery of protein therapeutics.
| 
View Cart
